US Patent

US11400065 — Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state

Method of Use · Assigned to Flamel Ireland Ltd · Expires 2037-07-21 · 11y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects oral pharmaceutical compositions of sodium oxybate with improved pharmacokinetic properties when taken shortly after eating.

USPTO Abstract

Oral pharmaceutical compositions of sodium oxybate having improved pharmacokinetic properties when administered less than two hours after eating are provided, and therapeutic uses thereof.

Drugs covered by this patent

sodium-oxybate (SODIUM OXYBATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3579`	—	sodium-oxybate
`U-3579`	—	sodium-oxybate
`U-3579`	—	sodium-oxybate
`U-3579`	—	sodium-oxybate

Patent Metadata

Patent number: US11400065
Jurisdiction: US
Classification: Method of Use
Expires: 2037-07-21
Drug substance claim: No
Drug product claim: No
Assignee: Flamel Ireland Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.